Member Info for Donato84

I am holding as near to the end of the deadline date which I think is around 30April, it looks like a lot of the bigger share holders have cashed their chips, means that the remaining circa 35% odd needed for the bid to be pushed through would come from individuals hands. If this is the case then redx may be trying to buy the shares in the open market, which would push the price I imagine, as there is a small float now available- I am no expert but I think if you google the takeover rules they need about 90% acceptance. If they have less by the end of the deadline the takeover could fail and Redmile could become just a large shareholder. There are many companies where the shares are tightly held and not a lot are available to the public, this is obviously not what Redmile want but they may not want to risk waiting right up to the deadline for individuals to respond to the offer document. This company should be worth so much more than 15.5p a lot of lesser bios out there riding the Corona bandwagon, its clear this company has interesting tech as two rival bids are after them. DYOR as always

My broker has not sent the offical offer document as of yet, I believe that once this document is published there is a 21 day period but I am not sure on this, there is also a general requirement for a 90% acceptance rate I think before they can push the deal through at 15.5p, the current shares outside of the bidders ownership is circa 32% they would need to buy a percentage of these in the market which may push the price a lot higher considering the available float and current share price, but who knows. I will be keeping an eye on this, also will be looking for the data due which could come out any moment now. Still a chance it get in with a potentially limited downside.

I am new to this stock I have been following it, does anyone know of the status of the sale iclaprim? I enjoy investing in biotechs and have had some great sucesses in this field. As seen lately the sector seems hot with this epidemic unravelling there is demand for companies doing useful things in the world of medicine.

I think its 75 or 90% acceptance needed for the takeover to go through, so even if 50% are accounted for if people dont want to see this go for cheap they will vote accordingly. I for one think the company is working on various things that are worth a lot more than this measley offer price, Redx Anti-Infectives for example is an interesting subsidiary, also the company should have clinical data due for RXC004 one of their main assets, this I believe was due to complete around March 2020. This takeover looks like its trying to get pushed through quickly, with two seperate bidders, I do not understand though and maybe someone can explain to me why Redmile are able to pick up so many additional shares and the price has not moved up? I think there is still scope for this to get an enhanced bid for the available shares correct me if I am wrong, possibly by another interested party or if new data comes out valuing the companies drug targets higher. DYOR

People do not really understand the potential here, this company is one of the few out there dealing with fibrosis ( scar tissue) it is believed that covid19 causes lung fibrosis, this company could be developing a way to reverse this damage done to the lungs (IPF). A number of big trades post TO offer announcement would indicate a potential to go possibly higher from here. The date I believe is 14th April, but with Redmile holding nearly 50% of the stock there could be a good move to the upside if it is believed the company is worth more than 30million, (which I believe personally is a super low ball figure) 15.5p should be more like 60p which gives a MCAP of approx £116m should be nearer to a reasonable valuation. DYOR as always.

First post here, been keeping an eye on this company for quite a while now, for me it looks very interesting, the company have a deal with Jazz pharma in the US for royalties up to 200million US, obviously this might take a while to get going, but it is this ROCK2 inhibitor technology which will be a game changer if proven. Currently the market for a NASH (fatty liver disease) solution is in the billions, with no FDA approved drug as of yet, this is an exciting market to be getting involved with. Even though the takeover didn’t go to plan I would be very interested to know the offer that was rejected. With a current mcap of 14million with funding being announced and over 40 percent of the share float unavailable, good luck getting into this one early. In my opinion this is well over a £1 with the right data. Bio pharma seems to be the big play at the moment with the Coronavirus, etc, this will be one to watch..